Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis

Inflammatory Bowel Diseases

Volumn 23, Issue 1, 2017, Pages 116-125

  Ishikawa, Dai ^a   Sasaki, Takashi ^a   Osada, Taro ^a   Kuwahara Arai, Kyoko ^a   Haga, Keiichi ^a   Shibuya, Tomoyoshi ^a   Hiramatsu, Keiichi ^a   Watanabe, Sumio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

AFM therapy; bacteroidetes; fecal microbiota transplantation; fresh FMT; ulcerative colitis

Indexed keywords

AMOXICILLIN; FOSFOMYCIN; METRONIDAZOLE; RNA 16S; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDETES; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMAN; INTESTINE FLORA; MALE; MICROBIOLOGICAL EXAMINATION; NAUSEA; NEXT GENERATION SEQUENCING; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; AGED; CLINICAL TRIAL; COLON; COMBINATION DRUG THERAPY; COMPLICATION; MICROBIOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PILOT STUDY; PROCEDURES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FOSFOMYCIN; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84997610371     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000975     Document Type: Article

References (39)

1. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140: 1785-1794.
2. Nemoto H, Kataoka K, Ishikawa H, et al. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig Dis Sci. 2012;57:2955-2964.
3. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146: 1489-1499.
4. Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145:946-953.
5. Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii reduction and inflammatory bowel disease: a meta-Analysis and systematic review of the literature. Gastroenterol Res Pract. 2014;2014: 872825.
6. Vindigni SM, Broussard EK, Surawicz CM. Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol. 2013;7: 615-628.
7. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368: 407-415.
8. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110-118. e4.
9. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-109. e6.
10. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37:42-47.
11. Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108:1620-1630.
12. Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820-1829.
13. Rossen NG, MacDonald JK, de Vries EM, et al. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol. 2015;21:5359-5371.
14. Owens C, Broussard E, Surawicz C. Fecal microbiota transplantation and donor standardization. Trends Microbiol. 2013;21:443-445.
15. Turner S, Pryer KM, Miao VP, et al. Investigating deep phylogenetic relationships among cyanobacteria and plastids by small subunit rRNA sequence analysis. J Eukaryot Microbiol. 1999;46:327-338.
16. Kawakami K, Inoue T, Murano M, et al. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol. 2015;21:1880-1886.
17. Osada T, Ohkusa T, Okayasu I, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol. 2009;23(suppl 2):S262-S267.
18. Fadrosh DW, Ma B, Gajer P, et al. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome. 2014;2:6.
19. Morgulis A, Coulouris G, Raytselis Y, et al. Database indexing for production MegaBLAST searches. Bioinformatics. 2008;24:1757-1764.
20. Huson DH, Mitra S, Ruscheweyh HJ, et al. Integrative analysis of environmental sequences using MEGAN4. Genome Res. 2011;21:1552-1560.
21. Igarashi H, Maeda S, Ohno K, et al. Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs. PLoS One. 2014;9:e107909.
22. Manichanh C, Reeder J, Gibert P, et al. Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Res. 2010;20: 1411-1419.
23. Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50:495-507.
24. Sokol H, Seksik P. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Curr Opin Gastroenterol. 2010;26: 327-331.
25. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79.
26. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-Associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:179-184.
27. Lee SM, Donaldson GP, Mikulski Z, et al. Bacterial colonization factors control specificity and stability of the gut microbiota. Nature. 2013;501: 426-429.
28. Crost EH, Pujol A, Ladire M, et al. Production of an antibacterial substance in the digestive tract involved in colonization-resistance against Clostridium perfringens. Anaerobe. 2010;16:597-603.
29. Yurdusev N, Nicolas JL, Ladire M, et al. Antagonistic effect exerted by three strictly anaerobic strains against various strains of Clostridium perfringens in gnotobiotic rodent intestines. Can J Microbiol. 1987;33: 226-231.
30. Miranda CM, Farias LM, Carvalho MA, et al. Purification and partial characterization of a bacteriocin isolated from Bacteroides ovatus H47. Can J Microbiol. 1993;39:169-174.
31. McGuckin MA, Linden SK, Sutton P, et al. Mucin dynamics and enteric pathogens. Nat Rev Microbiol. 2011;9:265-278.
32. Sheng YH, Hasnain SZ, Florin TH, et al. Mucins in inflammatory bowel diseases and colorectal cancer. J Gastroenterol Hepatol. 2012;27:28-38.
33. McGuckin MA, Hasnain SZ. There is a 'uc' in mucus, but is there mucus in UC?. Gut. 2014;63:216-217.
34. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016; 315:142-149.
35. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013; 78:240-249.
36. Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761-767.
37. Kahn SA, Vachon A, Rodriquez D, et al. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013;19:1506-1513.
38. Lee JR, Muthukumar T, Dadhania D, et al. Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS One. 2015;10:e0122399.
39. Shobar RM, Velineni S, Keshavarzian A, et al. The effects of bowel preparation on microbiota-related metrics differ in health and in inflammatory bowel disease and for the mucosal and luminal microbiota compartments. Clin Transl Gastroenterol. 2016;7:e143.